BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 36326739)

  • 1. American Thyroid Association Guidelines and National Trends in Management of Papillary Thyroid Carcinoma.
    Gordon AJ; Dublin JC; Patel E; Papazian M; Chow MS; Persky MJ; Jacobson AS; Patel KN; Suh I; Morris LGT; Givi B
    JAMA Otolaryngol Head Neck Surg; 2022 Dec; 148(12):1156-1163. PubMed ID: 36326739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trends in the Management of Localized Papillary Thyroid Carcinoma in the United States (2000-2018).
    Pasqual E; Sosa JA; Chen Y; Schonfeld SJ; Berrington de González A; Kitahara CM
    Thyroid; 2022 Apr; 32(4):397-410. PubMed ID: 35078347
    [No Abstract]   [Full Text] [Related]  

  • 3. Use of radioiodine after thyroid lobectomy in patients with differentiated thyroid cancer: does it change outcomes?
    Kiernan CM; Parikh AA; Parks LL; Solórzano CC
    J Am Coll Surg; 2015 Apr; 220(4):617-25. PubMed ID: 25667136
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is surgical resection without radioactive iodine treatment a safe alternative treatment for T1-2N1bM0 papillary thyroid carcinoma?
    Fujiwara T; Yoshizawa A; Mizuta M; Tamaki H
    Auris Nasus Larynx; 2021 Feb; 48(1):148-153. PubMed ID: 32718811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urban and Rural Surgical Practice Patterns for Papillary Thyroid Carcinoma.
    Collins RA; Chaves N; Lee G; Broekhuis JM; James BC
    Thyroid; 2023 Jul; 33(7):849-857. PubMed ID: 37014086
    [No Abstract]   [Full Text] [Related]  

  • 6. Are Evidence-Based Guidelines Reflected in Clinical Practice? An Analysis of Prospectively Collected Data of the Italian Thyroid Cancer Observatory.
    Lamartina L; Durante C; Lucisano G; Grani G; Bellantone R; Lombardi CP; Pontecorvi A; Arvat E; Felicetti F; Zatelli MC; Rossi R; Puxeddu E; Morelli S; Torlontano M; Crocetti U; Montesano T; Giubbini R; Orlandi F; Aimaretti G; Monzani F; Attard M; Francese C; Antonelli A; Limone P; Rossetto R; Fugazzola L; Meringolo D; Bruno R; Tumino S; Ceresini G; Centanni M; Monti S; Salvatore D; Spiazzi G; Mian C; Persani L; Barbaro D; Nicolucci A; Filetti S
    Thyroid; 2017 Dec; 27(12):1490-1497. PubMed ID: 29020892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radioactive iodine in low- to intermediate-risk papillary thyroid cancer.
    Zhao H; Gong Y
    Front Endocrinol (Lausanne); 2022; 13():960682. PubMed ID: 36034423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Total thyroidectomy versus thyroid lobectomy for papillary thyroid cancer: Comparative analysis after propensity score matching: A multicenter study.
    Kuba S; Yamanouchi K; Hayashida N; Maeda S; Adachi T; Sakimura C; Kawakami F; Yano H; Matsumoto M; Otsubo R; Sato S; Fujioka H; Kuroki T; Nagayasu T; Eguchi S
    Int J Surg; 2017 Feb; 38():143-148. PubMed ID: 27677707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features: Epidemiology and Long-Term Outcomes in a Strictly Defined Cohort.
    Chung R; Guan H; Ponchiardi C; Cerda S; Marwaha N; Yilmaz OH; Pinjic E; McAneny D; Lee SL; Drake FT
    Thyroid; 2021 Jan; 31(1):68-75. PubMed ID: 32539676
    [No Abstract]   [Full Text] [Related]  

  • 10. Trends and Outcomes of Surgical Management of Primary Papillary Carcinoma in the Pediatric Population.
    Sharma RK; Huang B; Lee JA; Kuo JH
    J Surg Res; 2021 Jul; 263():207-214. PubMed ID: 33690052
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radioactive iodine does not improve overall survival for patients with aggressive variants of papillary thyroid carcinoma less than 2 cm.
    Holoubek SA; MacKinney EC; Khokar AM; Kuchta KM; Winchester DJ; Prinz RA; Moo-Young TA
    Surgery; 2022 Jan; 171(1):203-211. PubMed ID: 34384604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncocytic Papillary Thyroid Carcinoma and Oncocytic Poorly Differentiated Thyroid Carcinoma: Clinical Features, Uptake, and Response to Radioactive Iodine Therapy, and Outcome.
    Lukovic J; Petrovic I; Liu Z; Armstrong SM; Brierley JD; Tsang R; Pasternak JD; Gomez-Hernandez K; Liu A; Asa SL; Mete O
    Front Endocrinol (Lausanne); 2021; 12():795184. PubMed ID: 34975765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Application of the new American Thyroid Association guidelines leads to a substantial rate of completion total thyroidectomy to enable adjuvant radioactive iodine.
    Kluijfhout WP; Pasternak JD; Drake FT; Beninato T; Shen WT; Gosnell JE; Suh I; C L; Duh QY
    Surgery; 2017 Jan; 161(1):127-133. PubMed ID: 27855968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The results of selective use of radioactive iodine on survival and on recurrence in the management of papillary thyroid cancer, based on Memorial Sloan-Kettering Cancer Center risk group stratification.
    Nixon IJ; Ganly I; Patel SG; Palmer FL; Di Lorenzo MM; Grewal RK; Larson SM; Tuttle RM; Shaha A; Shah JP
    Thyroid; 2013 Jun; 23(6):683-94. PubMed ID: 23742290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Total thyroidectomy versus lobectomy for intermediate-risk papillary thyroid carcinoma: A single-institution matched-pair analysis.
    Liu J; Zhang Z; Huang H; Xu S; Liu Y; Liu S; Wang X; Xu Z
    Oral Oncol; 2019 Mar; 90():17-22. PubMed ID: 30846171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective Use of Radioactive Iodine Therapy for Papillary Thyroid Cancers With Low or Lower-Intermediate Recurrence Risk.
    Grani G; Lamartina L; Alfò M; Ramundo V; Falcone R; Giacomelli L; Biffoni M; Filetti S; Durante C
    J Clin Endocrinol Metab; 2021 Mar; 106(4):e1717-e1727. PubMed ID: 33377969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Postoperative Surveillance in Older Adults With T1N0M0 Low-risk Papillary Thyroid Cancer.
    Pradhan MC; Kazaure HS; Wang F; Zambeli-Ljepovic A; Perkins JM; Stang MT; Scheri RP
    J Surg Res; 2021 Aug; 264():37-44. PubMed ID: 33765509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant radioactive iodine therapy is associated with improved survival for patients with intermediate-risk papillary thyroid cancer.
    Ruel E; Thomas S; Dinan M; Perkins JM; Roman SA; Sosa JA
    J Clin Endocrinol Metab; 2015 Apr; 100(4):1529-36. PubMed ID: 25642591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Knowledge of pathologically versus clinically negative lymph nodes is associated with reduced use of radioactive iodine post-thyroidectomy for low-risk papillary thyroid cancer.
    Ruel E; Thomas S; Dinan MA; Perkins JM; Roman SA; Sosa JA
    Endocrine; 2016 Jun; 52(3):579-86. PubMed ID: 26708045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of adjuvant radioactive iodine therapy with survival in node-positive papillary thyroid cancer.
    Sun Y; Gong J; Guo B; Shang J; Cheng Y; Xu H
    Oral Oncol; 2018 Dec; 87():152-157. PubMed ID: 30527231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.